Portola Pharmaceuticals to Present at the 2014 Wells Fargo

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA ) today announced that William Lis, chief executive officer, will present at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, at 8:20 a.m. Eastern Time in Boston.

The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that have the potential to represent significant advances in the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its first-in-class therapies. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions.

Betrixaban

Portola's wholly-owned, oral, once-daily Factor Xa inhibitor betrixaban is being evaluated in the only biomarker-based Phase 3 study for hospital-to-home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Betrixaban's distinct properties may have the potential to allow the agent to demonstrate efficacy without the significant increase in the rate of major bleeding that was seen in this patient population with other Factor Xa inhibitors. If approved, betrixaban could be the first anticoagulant for both hospital and post-discharge VTE prophylaxis and the standard of care in this large market of more than 20 million patients worldwide.  

Andexanet Alfa

Portola's second product candidate in the area of thrombosis, andexanet alfa, has the potential to be a first-in-class antidote to reverse the effects of Factor Xa inhibitors in patients who suffer a major bleeding episode or who require emergency surgery. Andexanet alfa has been designated as a breakthrough therapy by the U.S. Food and Drug Administration. Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors – Bristol-Myers Squibb and Pfizer (Eliquis® [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO® [rivaroxaban]), and Daiichi Sankyo (edoxaban) – while retaining all commercial rights to andexanet alfa.

Cerdulatinib* (PRT2070)

Portola's product candidate in the area of hematologic cancer, cerdulatinib, is an orally available molecule that uniquely inhibits two validated tumor proliferation pathways – spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being evaluated in a Phase 1/2 proof-of-concept study in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations.

 For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.

*Cerdulatinib is a proposed International Nonproprietary Name (pINN).

Investor Contact: Alexandra Santos Portola Pharmaceuticals 650.246.7239 Media Contact: Joey Fleury BrewLife 415.946.1090

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Core Lab's Quarterly Grit: Navigating a Turbulent Market

Updated Category News Views 0

Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...

Continue Reading
Wendy's Faces Takeover Bid Amid Strategic Focus Shift

Updated Category News Views 87

Behind the Unsolicited Offer Folks, it looks like Wendy's (NASDAQ:WEN) got itself mixed up in some high-stakes shenanigans. An unsolicited, non-binding proposal slammed into them, courtesy of the Investor Group led by Trian Partners, Flynn Group LP, BlueFive Capital, and Sixth Street Partners, itching to scoop up every last piece of Wendy’s stock they ain't already...

Continue Reading
Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 114

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading
BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 65

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
Raleigh's Auction Direct Stresses Oil Changes

Updated Category News Views 50

Keeping Engines Humming in Raleigh There's nothing quite like keeping an engine running like clockwork, especially in a place like Raleigh where folks rely on their rides day in and day out. That's where Auction Direct USA steps in, offering professional oil change services aimed at preserving the performance and reliability of used cars. A simple yet crucial service:...

Continue Reading
Caylent's Strategic Moves Gain Eyeballs in ISG Report

Updated Category News Views 103

Big Moves in the Contact Center Game There’s a buzz in the tech trenches, folks. Caylent just climbed onto the radar with its prominent mention in the 2026 ISG Provider Lens® Amazon Connect Ecosystem Report. Being dubbed a Product Challenger is no small feat when you’re pitted against some of the giants in tech. What’s their edge? An AI-first strategy, of course,...

Continue Reading
Long March Reflections: Lesson of Adaptation Endures

Updated Category News Views 22

Ever stood in a place where history feels so heavy you can almost touch it? That's Lazikou, a gorge in southern Gansu, where ninety years ago, young soldiers of China's Red Army faced a seemingly impassable barrier. Yet, they managed to climb, transform a military retreat into legend, and essentially shape the nation's path ahead. It's a feat that still sends ripples...

Continue Reading
OLX Rolls Out New AI Tools Amid Trust Issues

Updated Category News Views 78

A Grounded Approach to AI-Driven Market Evolution OLX Group's stepping into some turbulent waters, folks. They've dropped two new AI-assisted tools, Agentic Selling and DealFinder, while users are still trying to wrap their heads around trusting AI. Now, don't get me wrong, there's potential here—but the road ahead isn't paved with gold just yet. AI-Powered Tools Ready...

Continue Reading
TransCode Pursues Strategic Moves for TTX-MC138 Value

Updated Category News Views 56

A New Chapter for TransCode? Every once in a while, you find companies taking bold steps that make the market look twice. Today, that’s TransCode Therapeutics (NASDAQ: RNAZ) putting their chips on the table, determined to find the best route forward for their oncology efforts. Now, I’ve seen outfits talk plans without substance, but getting Tungsten Advisors on board...

Continue Reading

Top 5 Most Recently Viewed Articles

Cliquall Enhances Global Access with Language Support Update

Updated Category News Views 176

Cliquall Expands Global Access Through Multi-Language Support In an exciting development, Cliquall has unveiled its multi-language website and customer support system, aimed at enhancing accessibility and inclusivity for traders around the world. This innovative update now supports languages including Simplified Chinese, Traditional Chinese, Japanese, Korean, and English,...

Continue Reading
Understanding Riksbank's Auction Process for Government Bonds

Updated Category News Views 233

Riksbank's Auction Process for Government Bonds The Riksbank, Sweden's central bank, plays a crucial role in managing the country's monetary policy and influences the national economy. One of the key aspects of its operations is the auctioning of government bonds. This process is designed to facilitate the financing of government activities and provide crucial liquidity...

Continue Reading
Sony's IMX742: Revolutionizing Endoscopic Imaging

Updated Category News Views 60

Sony's Bold Move into Medical Tech You wouldn't expect a company like Sony to make waves in the medical field, but there they go again, shaking things up with their latest announcement. Lurking past the shiny consumer electronics, they've got the IMX742, a sensor designed for single-use endoscopes. A humble 1 mm square powerhouse, boasting about 0.51 megapixels of digital...

Continue Reading
Investigating Key Mergers: ACA, APGE, BOLD, GBCS

Updated Category News Views 7

Probing the Potential Pitfalls of Corporate Mergers Well, here's a situation where the lawyers are having a field day. Monteverde & Associates, perched up in the Empire State Building of all places, is nudging investors with a firm elbow as they dig into a quartet of mergers that involve Arcosa, Apogee Therapeutics, Boundless Bio, and Selectis Health. When legal eagles...

Continue Reading
Market Trends: Analyzing Recent Momo Stock Movements and Nvidia

Updated Category News Views 512

Understanding Recent Momo Stock Movements In today's dynamic market, it's crucial to grasp the ongoing trends that could significantly impact investing. Recently, a noticeable sell-off in momo stocks has taken place, influenced by an interplay of expectations and reality. Investors are encouraged to sharpen their focus on these movements and understand their implications....

Continue Reading